ATE511539T1 - Bhlh-pas-proteine, deren gene und verwendung derselben - Google Patents

Bhlh-pas-proteine, deren gene und verwendung derselben

Info

Publication number
ATE511539T1
ATE511539T1 AT01272819T AT01272819T ATE511539T1 AT E511539 T1 ATE511539 T1 AT E511539T1 AT 01272819 T AT01272819 T AT 01272819T AT 01272819 T AT01272819 T AT 01272819T AT E511539 T1 ATE511539 T1 AT E511539T1
Authority
AT
Austria
Prior art keywords
amino acid
regulatory factor
transcription regulatory
level
neurocyte
Prior art date
Application number
AT01272819T
Other languages
English (en)
Inventor
Norihisa Ohe
Original Assignee
Sumitomo Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Chemical Co filed Critical Sumitomo Chemical Co
Application granted granted Critical
Publication of ATE511539T1 publication Critical patent/ATE511539T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT01272819T 2000-12-27 2001-12-17 Bhlh-pas-proteine, deren gene und verwendung derselben ATE511539T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000398548 2000-12-27
JP2001077740 2001-03-19
PCT/JP2001/011064 WO2002053729A1 (fr) 2000-12-27 2001-12-17 Proteines bhlh, leurs genes et leurs utilisations

Publications (1)

Publication Number Publication Date
ATE511539T1 true ATE511539T1 (de) 2011-06-15

Family

ID=26606895

Family Applications (3)

Application Number Title Priority Date Filing Date
AT01272511T ATE393168T1 (de) 2000-12-27 2001-12-17 Transkriptionsaktivierungskomplex und dessen verwendung
AT01272818T ATE397664T1 (de) 2000-12-27 2001-12-17 Verfahren zur untersuchung der fähigkeit zur kontrolle der nervenzellplastizität
AT01272819T ATE511539T1 (de) 2000-12-27 2001-12-17 Bhlh-pas-proteine, deren gene und verwendung derselben

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT01272511T ATE393168T1 (de) 2000-12-27 2001-12-17 Transkriptionsaktivierungskomplex und dessen verwendung
AT01272818T ATE397664T1 (de) 2000-12-27 2001-12-17 Verfahren zur untersuchung der fähigkeit zur kontrolle der nervenzellplastizität

Country Status (6)

Country Link
US (3) US20040110171A1 (de)
EP (3) EP1354889B1 (de)
AT (3) ATE393168T1 (de)
CA (3) CA2433501C (de)
DE (2) DE60134342D1 (de)
WO (3) WO2002053735A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190653A1 (en) * 2002-01-11 2003-10-09 Mehrdad Shamloo Regulated gene in the pathophysiology of ischemic stroke
US7618947B2 (en) 2004-08-25 2009-11-17 Isis Pharmaceuticals, Inc. Modulation of HIF-1 beta expression
JP2007282501A (ja) * 2006-03-24 2007-11-01 Sumitomo Chemical Co Ltd アポトーシス制御能力の検定方法
JP2007282502A (ja) * 2006-03-24 2007-11-01 Sumitomo Chemical Co Ltd 細胞変性制御能力の検定方法
US11889986B2 (en) 2010-12-09 2024-02-06 Endochoice, Inc. Flexible electronic circuit board for a multi-camera endoscope

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757524B1 (fr) * 1996-12-19 1999-01-29 Rhone Poulenc Rorer Sa Polypeptides de la famille bhlh, sequences d'acides nucleiques correspondantes
US5840532A (en) * 1997-01-21 1998-11-24 Board Of Regents, The University Of Texas System Neuronal bHLH-PAS domain proteins
US7105647B1 (en) * 1997-11-28 2006-09-12 Wisconsin Alumni Research Foundation cDNAs and proteins involved in hypoxia, circadian and orphan signal transduction pathways, and methods of use
US6780642B2 (en) * 2000-08-04 2004-08-24 Florida Atlantic University Association of SIM2 with cancer
US20030190653A1 (en) * 2002-01-11 2003-10-09 Mehrdad Shamloo Regulated gene in the pathophysiology of ischemic stroke

Also Published As

Publication number Publication date
US20040248247A1 (en) 2004-12-09
CA2433495A1 (en) 2002-07-11
US20060216705A1 (en) 2006-09-28
CA2433495C (en) 2011-10-18
CA2433501C (en) 2011-07-19
EP1354946A4 (de) 2005-01-05
WO2002053729A1 (fr) 2002-07-11
EP1354946A1 (de) 2003-10-22
CA2433492A1 (en) 2002-07-11
ATE397664T1 (de) 2008-06-15
CA2433501A1 (en) 2002-07-11
EP1354951A4 (de) 2004-12-29
EP1354946B1 (de) 2011-06-01
WO2002053736A1 (fr) 2002-07-11
DE60133774T2 (de) 2009-05-28
US7541189B2 (en) 2009-06-02
DE60134342D1 (de) 2008-07-17
EP1354889B1 (de) 2008-04-23
US7129065B2 (en) 2006-10-31
DE60133774D1 (de) 2008-06-05
EP1354889A4 (de) 2004-12-29
EP1354951A1 (de) 2003-10-22
ATE393168T1 (de) 2008-05-15
EP1354889A1 (de) 2003-10-22
WO2002053735A1 (fr) 2002-07-11
EP1354951B1 (de) 2008-06-04
US20040110171A1 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
ATE211506T1 (de) Ein verfahren zum nachweis biologisch aktiver substanzen
ATE488588T1 (de) Verfahren zur kennzeichnung mesenchymaler stammzellen unter verwendung verschiedener marker
DE3851289D1 (de) Verfahren zur Züchtung rekombinanter Zellen.
CA2403817A1 (en) Methods of modulating hair growth
NO308312B1 (no) FremgangsmÕte til fremstilling av et kimerisk protein, DNA- molekyl som koder proteinet, rekombinant DNA-molekyl og celle som omfatter DNA-molekylet
WO2003078962A3 (en) Detection and quantification of modified proteins
EP1170380A3 (de) Zusammensetzungen und Verfahren zur Bestimmung antiviraler Wirkstoff Suszeptibilität und Resistenz sowie antivirales Wirkstoff-Screening
WO1999064592A3 (en) Green fluorescent proteins for measuring the ph of a biological sample
ATE421697T1 (de) Verfahren zur identifizierung von verbindungen, die transmembran-proteine beeinflussen
ATE511539T1 (de) Bhlh-pas-proteine, deren gene und verwendung derselben
CA2044626A1 (en) Type a platelet-derived growth factor receptor gene
ATE412775T1 (de) Verfahren zur quantifizierung von nukleinsäuren mittels bestimmung der zellzahl
ATE491037T1 (de) Verfahren zum zählen von bakterien, bakterienzählgerät und für das zählgerät vewendete zelle
ATE312939T1 (de) Verfahren zur rekombinanten herstellung von polypeptiden
DE60216721D1 (de) Verfahren zum Nachweis von Protein-Proteininteraktionen in Membranen
ATE421693T1 (de) Proteine in der diabetes-proteomanalyse
WO2002050104A3 (en) Methods and cells for detecting modulators of rgs proteins
AU2001276569B2 (en) Quantitative fluorescent assay for determining the activity of transport proteins
RU2008152780A (ru) Ген, вовлеченный в иммортализацию раковой клетки человека, и его применение
EP1143011A3 (de) Verfahren zum Nachweis von biologisch aktiven Substanzen
FR2786787B1 (fr) Methode d'analyse in vitro d'un phenotype connu a partir d'un echantillon d'acides nucleiques
Meer Smooth muscle myosin heavy chain isoform levels and unloaded shortening in single smooth muscle cells
HUP0303646A2 (hu) ABCG2-féltranszporter fehérje expresszióján alapuló szkrínelő rendszer
WO2003035866A1 (fr) Procede d'evaluation et d'identification de molecule biologiquement fonctionnelle a l'aide d'un gene marqueur
MACKAY-SIM CHAPTER ELECTRONIC SENSOR

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties